Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC 50 values of 12.4 nM and 9.9 nM, respectively. Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal s
In Vitro:Dalpiciclib hydrochloride (0-4 μM, 72 h) inhibits cell proliferation in a dose-dependent manner. Dalpiciclib hydrochloride (0-10 μM, 6 d) inhibits the proliferation of retinoblastoma-positive tumor cell lines. MCE has not independently confirmed
In Vivo:Dalpiciclib hydrochloride (oral gavage; 150mg/kg; once weekly; 3 weeks) shows antitumor activity against ESCC xenografts. Dalpiciclib hydrochloride combined with Paclitaxel (PTX) or Cisplatin (CDDP) offer synergistic inhibitory effects in ESCC xenog
Biological Activity:Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC 50 values of 12.4u2009nM and 9.9u2009nM, respectively . Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esop